FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1589-1600 April 13, 2006 Number 15 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Little, F. F. Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background We conducted a double-blind, randomized, placebo-controlled study to evaluate the efficacy of telithromycin in patients with acute exacerbations of asthma.

Methods A total of 278 adults with diagnosed asthma were enrolled within 24 hours after an acute exacerbation of asthma requiring short-term medical care. The patients were randomly assigned to receive 10 days of oral treatment with telithromycin (at a dose of 800 mg daily) or placebo in addition to usual care. Primary efficacy end points were a change from baseline over the treatment period in symptoms (as recorded by patients in a diary card) and in the peak expiratory flow in the morning at home. The presence of Chlamydophila pneumoniae or Mycoplasma pneumoniae was ascertained by serologic analysis, polymerase chain reaction, and culture.

Results Of the two prespecified primary outcomes, only asthma symptoms showed a significantly greater reduction among patients receiving telithromycin than among those receiving placebo. Mean (±SD) scores on a test of asthma symptoms (on a 7-point scale, with 0 denoting no symptoms and 6 denoting severe symptoms) were 3.0±1.4 at baseline and 1.7±1.1 at the end of treatment for the telithromycin group and 2.8±1.3 at baseline and 2.0±1.0 at the end of treatment for the placebo group. The mean decrease in symptom scores during the treatment period was 1.3 for telithromycin and 1.0 for placebo (mean difference, –0.3; 95 percent confidence interval, –0.5 to –0.1; P=0.004). There was no significant treatment effect on the other primary outcome measure, a change in morning peak expiratory flow. Nausea was more common among patients in the telithromycin group than in the placebo group (P=0.01). Although 61 percent of patients had evidence of infection with C. pneumoniae, M. pneumoniae, or both, there was no relationship between bacteriologic status and the response to asthma treatment.

Conclusions This study provides evidence of the benefit of telithromycin in patients with acute exacerbations of asthma; the mechanisms of benefit remain unclear. (ClinicalTrials.gov number, NCT00273520 [ClinicalTrials.gov] .)

Source Information

From the National Heart and Lung Institute, Imperial College London (S.L.J.); and G.R. Micro (D.J.F.) — both in London; the University of Milan, Istituto di Ricovero e cura a Carattere Scientifico Policlinico, Milan (F.B.); the University of Auckland, Auckland, New Zealand (P.N.B.); the National Jewish Medical and Research Center, Denver (R.J.M.); and Sanofi-Aventis, Bridgewater, N.J. (R.B.N.).

Address reprint requests to Dr. Johnston at the Department of Respiratory Medicine, National Heart and Lung Institute and Wright Fleming Institute of Infection and Immunity, Imperial College London, Norfolk Pl., London W2 1PG, United Kingdom, or at s.johnston{at}imperial.ac.uk.

Full Text of this Article

Related Letters:

Telithromycin in Acute Exacerbations of Asthma
Caramori G., Papi A., Mutgi A., Hammersley J., Kuramochi Y., Morita T., Osawa R., Andraws R., Johnston S. L., Nieman R. B., the Telithromycin, Chlamydophila, and Asthma Trial Investigators
Extract | Full Text | PDF  
N Engl J Med 2006; 355:96-98, Jul 6, 2006. Correspondence

Telithromycin and Acute Liver Failure
Graham D. J.
Extract | Full Text | PDF  
N Engl J Med 2006; 355:2260-2261, Nov 23, 2006. Correspondence

This article has been cited by other articles:

• Krishnan, J. A., Nowak, R., Davis, S. Q., Schatz, M. (2009). Anti-inflammatory Treatment after Discharge Home from the Emergency Department in Adults with Acute Asthma. Proc Am Thorac Soc 6: 380-385 [Full Text]  
• Beigelman, A., Gunsten, S., Mikols, C. L., Vidavsky, I., Cannon, C. L., Brody, S. L., Walter, M. J. (2009). Azithromycin Attenuates Airway Inflammation in a Noninfectious Mouse Model of Allergic Asthma. Chest 136: 498-506 [Abstract] [Full Text]  
• Newcomb, D. C., Peebles, R. S. Jr. (2009). Bugs and Asthma: A Different Disease?. Proc Am Thorac Soc 6: 266-271 [Abstract] [Full Text]  
• Crosbie, P. A. J., Woodhead, M. A. (2009). Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 33: 171-181 [Abstract] [Full Text]  
• Ishimoto, H., Mukae, H., Sakamoto, N., Amenomori, M., Kitazaki, T., Imamura, Y., Fujita, H., Ishii, H., Nakayama, S., Yanagihara, K., Kohno, S. (2009). Different effects of telithromycin on MUC5AC production induced by human neutrophil peptide-1 or lipopolysaccharide in NCI-H292 cells compared with azithromycin and clarithromycin. J Antimicrob Chemother 63: 109-114 [Abstract] [Full Text]  
• Vanaudenaerde, B. M., Meyts, I., Vos, R., Geudens, N., De Wever, W., Verbeken, E. K., Van Raemdonck, D. E., Dupont, L. J., Verleden, G. M. (2008). A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J 32: 832-842 [Abstract] [Full Text]  
• Gibson, P. G. (2008). A Light at the End of the Tunnel of Inflammation in Obstructive Airway Diseases?. Chest 134: 475-476 [Full Text]  
• Pallan, S., Mahony, J. B., O'Byrne, P. M., Nair, P. (2008). Asthma Management by Monitoring Sputum Neutrophil Count. Chest 134: 628-630 [Abstract] [Full Text]  
• Sykes, A., Seemungal, T., ICEAD contributors, (2008). Recent advances in exacerbations of asthma. Thorax 63: 758-760 [Full Text]  
• Chmura, K., Bai, X., Nakamura, M., Kandasamy, P., McGibney, M., Kuronuma, K., Mitsuzawa, H., Voelker, D. R., Chan, E. D. (2008). Induction of IL-8 by Mycoplasma pneumoniae membrane in BEAS-2B cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 295: L220-L230 [Abstract] [Full Text]  
• Oliver, B G G, Lim, S, Wark, P, Laza-Stanca, V, King, N, Black, J L, Burgess, J K, Roth, M, Johnston, S L (2008). Rhinovirus exposure impairs immune responses to bacterial products in human alveolar macrophages. Thorax 63: 519-525 [Abstract] [Full Text]  
• Hanania, N. A. (2008). Targeting Airway Inflammation in Asthma: Current and Future Therapies. Chest 133: 989-998 [Abstract] [Full Text]  
• Sykes, A., Mallia, P., Johnston, S. L. (2007). Diagnosis of Pathogens in Exacerbations of Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 4: 642-646 [Abstract] [Full Text]  
• Sutherland, E. R., Martin, R. J. (2007). Asthma and Atypical Bacterial Infection. Chest 132: 1962-1966 [Abstract] [Full Text]  
• Droemann, D., Rupp, J., Goldmann, T., Uhlig, U., Branscheid, D., Vollmer, E., Kujath, P., Zabel, P., Dalhoff, K. (2007). Disparate Innate Immune Responses to Persistent and Acute Chlamydia pneumoniae Infection in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 175: 791-797 [Abstract] [Full Text]  
• Pavord, I. D (2007). Non-eosinophilic asthma and the innate immune response. Thorax 62: 193-194 [Full Text]  
• Graham, D. J. (2006). Telithromycin and acute liver failure.. NEJM 355: 2260-2261 [Full Text]  
• Caramori, G., Papi, A., Mutgi, A., Hammersley, J., Kuramochi, Y., Morita, T., Osawa, R., Andraws, R., Johnston, S. L., Nieman, R. B., the Telithromycin, Chlamydophila, and Asthma Trial, (2006). Telithromycin in acute exacerbations of asthma.. NEJM 355: 96-97 [Full Text]  
• Reddel, H. K., Barnes, D. J. (2006). Pharmacological strategies for self-management of asthma exacerbations.. Eur Respir J 28: 182-199 [Abstract] [Full Text]  
• Wunderink, R. G. (2006). A CAP on Antibiotic Duration.. Am. J. Respir. Crit. Care Med. 174: 3-5 [Full Text]  
• (2006). Antibiotics for Asthma? Maybe Yes, Maybe No. JWatch Emergency Med. 2006: 7-7 [Full Text]  
• (2006). Antibiotics for Asthma?. JWatch General 2006: 2-2 [Full Text]  
• Little, F. F. (2006). Treating Acute Asthma with Antibiotics -- Not Quite Yet. NEJM 354: 1632-1634 [Full Text]